We have entered into a key partnership with Beurer Gmbh, one of the top 3 distributors of Blood Glucose meters in Germany, Austria, and Italy.
After extensive due diligence, Beurer decided to invest 2m€ (out of a global investment of 2.25m€) to help further develop the K’Watch and begin human clinical trials. They have acquired exclusive commercialization rights in Germany, Austria, and Italy.
Patient-friendly and cost-effective, Beurer believes that K’Watch will become a leading product to measure blood glucose levels in real-time.
|According to Marco Bühler, Managing Director of Beurer Gmbh, ” PKvitality has one of the strongest teams and technology portfolio in the area of future Glucose monitoring applied to Continuous Glucose Monitoring. The concept of realizing a CGM in a smartwatch that is basically pain-free and non-stigmatizing in combination with a much more cost-efficient sensor patch is convincing. We are looking forward to launching the K’Watch in our key territories, and are convinced that this patient-friendly and the cost-effective device will meet a large success”
If you are interested in investing in PKvitality, you can meet us at the Biotech and Medtech showcase, a satellite event to JP Morgan Healthcare Conference, from 13th to 15th January 2020 in San Francisco, California, or send inquiries to email@example.com.